It works by activating GLP-1 receptors in the body, which helps regulate appetite and slow gastric emptying supporting reduced caloric intake over time
Weight reduction may reduce limb volume, decrease inflammatory mediators, and improve lymphatic vessel function, potentially alleviating lymphoedema symptoms
Because both semaglutides effects and alcohol can irritate the gastrointestinal tract, combining them makes these unpleasant symptoms more likely
[And] dont force yourself to eat when youre not hungry.
#Pharma #GLP1 #ObesityTreatment #DrugDevelopment #HealthcareInnovation #EliLilly #NovoNordisk #PharmaceuticalIndustry To view or add a comment, sign in NEW DRUG APPROVAL ALERT The FDA has approved Foundayo (orforglipron), a new once-daily oral GLP-1 for chronic weight management in adults with obesity, or adults with overweight plus at least one weight-related condition
OCULAR ADVERSE EFFECTS Other cancers Recent investigations have highlighted the association between various neoplasms, such as thyroid, breast, and cholangiocarcinoma, and GLP-1 RAs [105-107]
